Axsome Therapeutics Q3 2026 Results: Net Loss of $12.9M, Loss Narrows
Axsome Therapeutics reported total revenues of $259.7 million for the third quarter of 2026, driven primarily by product sales of AUVELITY, SUNOSI, and SYMBRAVO. While the company remains in a net loss position of $12.9 million for the quarter, this represents a significant improvement from the $47.2 million loss in the prior year period as commercial scale increases.
- Key figure
- Net loss $12.9M